Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02959463 · OUTCOME

Progression-Free Survival (PFS)

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma · Source last updated 2026-05-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Every 6 weeks (42 +/- 7 days) until to 48 weeks, then every 12 weeks (+/- 7 days) to 5 years

What was measured

To assess progression-free survial (PFS) in patients receiving Pembrolizumab after radiation therapy for MPM.

Groups in this outcome

Cohort 1

Patient with lung intact to receive hemithoracic radiation therapy for definitive intent

Cohort 2

Patients with lung intact to receive non-hemithoracic radiation therapy(palliative radiation therapy)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 112
Cohort 212

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Cohort 17.7Not reported4.219.8Not reported
Cohort 24Not reported3.311.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4.2
        upper Limit
        19.8
        value
        7.7
      2. group Id
        OG001
        lower Limit
        3.3
        upper Limit
        11.4
        value
        4
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    2. group Id
      OG001
      value
      12
    units
    Participants
description
To assess progression-free survial (PFS) in patients receiving Pembrolizumab after radiation therapy for MPM.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patient with lung intact to receive hemithoracic radiation therapy for definitive intent
    id
    OG000
    title
    Cohort 1
  2. description
    Patients with lung intact to receive non-hemithoracic radiation therapy(palliative radiation therapy)
    id
    OG001
    title
    Cohort 2
param Type
MEAN
reporting Status
POSTED
time Frame
Every 6 weeks (42 +/- 7 days) until to 48 weeks, then every 12 weeks (+/- 7 days) to 5 years
title
Progression-Free Survival (PFS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice